Nektar Therapeutics (NKTR) News Today $60.10 -3.54 (-5.56%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$60.22 +0.12 (+0.20%) As of 10/24/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NKTR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Nektar Therapeutics (NASDAQ:NKTR) Receives Sell (D-) Rating from Weiss Ratings3 hours ago | marketbeat.com12 Hot Stocks to Buy with Huge Upside PotentialOctober 24 at 11:51 AM | insidermonkey.comNektar Therapeutics (NASDAQ:NKTR) Reaches New 12-Month High - Here's What HappenedOctober 24 at 5:51 AM | marketbeat.comNektar Therapeutics: Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific MeetingOctober 22, 2025 | finanznachrichten.deData from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific MeetingOctober 22, 2025 | prnewswire.comIFP Advisors Inc Invests $124,000 in Nektar Therapeutics $NKTROctober 19, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Trading 3.8% Higher - Here's WhyOctober 18, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Sets New 12-Month High - What's Next?October 18, 2025 | marketbeat.comNektar Therapeutics gains amid takeover speculationOctober 17, 2025 | msn.comNektar Therapeutics (NASDAQ:NKTR) Given Average Rating of "Moderate Buy" by BrokeragesOctober 16, 2025 | marketbeat.comFDA Fast Track for Eczema Therapy Could Be a Game Changer for Nektar Therapeutics (NKTR)October 14, 2025 | finance.yahoo.comNektar Therapeutics (NKTR): Assessing Valuation After a Strong Multi-Month Share Price RallyOctober 13, 2025 | finance.yahoo.comWealth Enhancement Advisory Services LLC Reduces Stake in Nektar Therapeutics $NKTROctober 11, 2025 | marketbeat.comNektar Therapeutics' (NKTR) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 10, 2025 | marketbeat.comGainplan LLC Buys New Shares in Nektar Therapeutics $NKTROctober 8, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Sells 121,001 Shares of Nektar Therapeutics $NKTROctober 8, 2025 | marketbeat.comHere's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in SeptemberOctober 5, 2025 | fool.comNektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week High - Time to Buy?October 2, 2025 | marketbeat.comVoya Investment Management LLC Raises Stock Holdings in Nektar Therapeutics $NKTROctober 1, 2025 | marketbeat.comParallel Advisors LLC Sells 14,767 Shares of Nektar Therapeutics $NKTRSeptember 28, 2025 | marketbeat.comGoldman Sachs Group Inc. Decreases Position in Nektar Therapeutics $NKTRSeptember 28, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Trading 5.8% Higher - What's Next?September 26, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Price Down 6.9% - Time to Sell?September 25, 2025 | marketbeat.comPalumbo Wealth Management LLC Takes Position in Nektar Therapeutics $NKTRSeptember 25, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $105.00September 23, 2025 | marketbeat.comThese 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?September 21, 2025 | fool.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 21, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Shares Down 5.1% - Here's What HappenedSeptember 20, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Earns Buy Rating from BTIG ResearchSeptember 20, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Shares Gap Up - Here's What HappenedSeptember 19, 2025 | marketbeat.comWhy Nektar Therapeutics Stock Zoomed More Than 15% Higher TodaySeptember 18, 2025 | fool.comNektar Therapeutics stock surges on positive atopic dermatitis dataSeptember 18, 2025 | investing.comNektar Therapeutics shares jump after positive atopic dermatitis trial resultsSeptember 18, 2025 | msn.comWhy Is Nektar Therapeutics Stock Trading Lower On Thursday?September 18, 2025 | benzinga.comWhy Is Nektar Therapeutics Stock Trading Lower On Thursday?September 18, 2025 | benzinga.comNektar Therapeutics (NASDAQ:NKTR) Hits New 52-Week High - Still a Buy?September 18, 2025 | marketbeat.comNektar Therapeutics Reveals Promising Phase 2b Study ResultsSeptember 18, 2025 | tipranks.comNektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025September 18, 2025 | prnewswire.comPiper Sandler Keeps Their Buy Rating on Nektar Therapeutics (NKTR)September 16, 2025 | theglobeandmail.comAcadian Asset Management LLC Purchases 100,645 Shares of Nektar Therapeutics $NKTRSeptember 15, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Sets New 1-Year High - Should You Buy?September 13, 2025 | marketbeat.comFred Alger Management LLC Buys New Holdings in Nektar Therapeutics $NKTRSeptember 13, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $2.05 Million Holdings in Nektar Therapeutics $NKTRSeptember 13, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Sells $311,235.54 in StockSeptember 12, 2025 | insidertrades.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 1,721 Shares of StockSeptember 10, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin Sells 5,166 SharesSeptember 10, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) CEO Howard Robin Sells 6,666 SharesSeptember 10, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Trading 7.3% Higher - Time to Buy?September 10, 2025 | marketbeat.comNektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025September 9, 2025 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 1,721 SharesSeptember 9, 2025 | insidertrades.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.790.84▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼76▲NKTR Articles Average Week Get the Latest News and Ratings for NKTR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Nektar Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PRGO News Today SUPN News Today PCRX News Today OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
